Eisai Presents new Research for Investigational Compound Lenvatinib at the European Society for Medical Oncology

Description

Eisai Presents new Research for Investigational Compound Lenvatinib at the European Society for Medical Oncology PR Newswire VIENNA, Austria, October 1, 2012 VIENNA, Austria, October 1, 2012 /PRNewswire/ -- INTENDED FOR EUROPEAN MEDIA ONLY Results from a Phase I/II trial of the investigational compound lenvatinib (E7080), a multi-targeted, kinase inhibitor, in people with advanced hepatocellular cancer have been presented at the ESMO 2012 Congress (European Society for Medical Oncology) taking place on Friday 28 September - [1]Tuesday 2 October. Two other studies were presented, reporting the results of lenvatinib in the treatment of recurrent glioblastoma (the most common type of brain cancer which is almost universally fatal) and lenvatinib in [2],[3]combination with everolimus in metastatic renal cell carcinoma. The following Eisai posters were presented at this year's ESMO 2012 Congress: A Phase 2 Trial of the Multi-targeted Kinase Inhibitor Lenvatinib (E7080) in Lenvatinib (E7080) Patients With Recurrent Glioblastoma (GBM) and Disease Progression Following Abstract No: 417PD Prior Bevacizumab Treatment Poster Session D.A. Reardon, E. Pan, J. Fan, J. Mink, D. Barboriak, J.J. Vredenburgh, A. Saturday 29th Desjardins, K. Peters, J.P. O'Brien, P.

Informations

• Publié par: eisai-europe-limited
• Nombre de lectures: 25
• Langue: English

Extrait

Eisai Presents new Research for

Investigational Compound Lenvatinib at the

European Society for Medical Oncology

PR Newswire

VIENNA, Austria, October 1, 2012

VIENNA, Austria

,

October 1, 2012

/PRNewswire/ --

INTENDED FOR EUROPEAN MEDIA ONLY

Results from a Phase I/II trial of the investigational compound lenvatinib

(E7080), a multi-targeted, kinase inhibitor, in people with advanced

hepatocellular cancer have been presented at the ESMO 2012 Congress

(European Society for Medical Oncology) taking place on Friday 28 September -

Tuesday 2 October.

[1]

Two other studies were presented, reporting the results

of lenvatinib in the treatment of recurrent glioblastoma (the most common

type of brain cancer which is almost universally fatal) and lenvatinib in

combination with everolimus in metastatic renal cell carcinoma.

[2],[3]

The following Eisai posters were presented at this year's ESMO 2012 Congress:

A Phase 2 Trial of the Multi-targeted

Kinase Inhibitor Lenvatinib (E7080) in

Lenvatinib (E7080)

Patients With Recurrent Glioblastoma

(GBM) and Disease Progression Following

Abstract No: 417PD

Prior Bevacizumab Treatment

Poster Session

D.A. Reardon, E. Pan, J. Fan, J. Mink,

D. Barboriak, J.J. Vredenburgh, A.

Saturday 29th

Desjardins, K. Peters, J.P. O'Brien, P.

September 13:00-14:00

Wen

A Phase Ib Clinical Trial of the

Lenvatinib (E7080)

Multi-targeted Kinase Inhibitor

Lenvatinib (E7080) in Combination With

Abstract No: 814P

Everolimus for Treatment of Metastatic

Renal Cell Carcinoma (RCC)

Poster Session

A.M. Molina, T.E. Hutson, J.M.G.

Saturday 29th

Larkin, A. Gold, C. Andresen, K. Wood,

September 13:00-14:00

R. Motzer, M.D. Michaelson

Lenvatinib (E7080)

Phase I/II Trial of Lenvatinib (E7080),

a Multi-targeted Tyrosine Kinase

Abstract No: 737P

Inhibitor, in Patients with Advanced

Hepatocellular Carcinoma (HCC)

Poster Session

K. Ikeda, H. Kumada, M. Kudo, S.

Sunday 30th September

Kawazoe, Y. Osaki, M. Ikeda, T.Okusaka,

13:00-14:00

T. Suzuki, J P O'Brien, K. Okita

"Presentation of these data at ESMO demonstrates continued progress in the

development of lenvatinib. Eisai's

human health care

mission is to help address

unmet medical needs and provide healthcare benefits to patients and their

families," says Dr Jim O'Brien, Eisai's Lenvatinib International Team Lead. "Our

commitment to the development of lenvatinib underscores our commitment to

this important mission."

Notes to Editors

Lenvatinib (E7080)

Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases

(RTKs), including KDR (VEGFR-2), Flt-1 (VEGFR-1), FGFR1, PDGFR-β and c-kit

involved in angiogenesis and tumour proliferation.

[4],[5]

It is currently being

investigated as a treatment for thyroid, hepatocellular, endometrial and other

solid tumour types.

Eisai in Oncology

Eisai is dedicated to discovering, developing and producing innovative oncology

therapies that can make a difference and impact the lives of patients and their

families. This passion for people is part of Eisai's human health care (hhc)

mission, which strives for better understanding of the needs of patients and

their families to increase the benefits health care provides. Our commitment to

meaningful progress in oncology research, built on scientific expertise, is

supported by a global capability to conduct discovery and preclinical research,

and develop small molecules, therapeutic vaccines, and biologic and supportive

care agents for cancer across multiple indications.

About Eisai:

Eisai recently expanded their UK Hatfield commercial, research and

manufacturing facility which now supports the company's growing EMEA

business.

Eisai concentrates its R&D activities in three key areas:

Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss

Oncology including: anticancer therapies; tumour regression, tumour suppression,

antibodies, etc

Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis,

psoriasis, inflammatory bowel disease

With operations in the U.S.,

Asia

,

Europe

and its domestic home market of

Japan

, Eisai employs more than 11,000 people worldwide. In

Europe

, Eisai

undertakes sales and marketing operations in over 20 markets, including the

United Kingdom

,

France

,

Germany

,

Italy

,

Spain

,

Switzerland

,

Sweden

,

Ireland

,

Austria

,

Denmark

,

Finland

,

Norway

,

Portugal

,

Iceland

,

Czech Republic

,

Slovakia

,

the Netherlands

,

Belgium

,

Luxembourg

, the

Middle East

and

Russia

.

For further information please visit our web site http://www.eisai.com.

References:

1. Ikeda, K. Kumada, H. Kudo, et al. Phase I/II trial of Lenvatinib (E7080), a

multi-targeted tyrosine kinase inhibitor, in patients with advanced

hepatocellular carcinoma. Poster presented at the ESMO Congress,

Vienna

,

2012

2. Reardon, D.A. Pan, E. Fan, et al. A Phase 2 Trial of the multi-targeted kinase

inhibitor lenvatinib (E7080) in patients with recurrent glioblastoma and disease

progression following prior bevacizumab treatment. Poster presented at the

ESMO Congress,

Vienna

, 2012

3. Molina, AM. Hutson, TE. Larkin, et al. A Phase Ib clinical trial of the multi-

targeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for

the treatment of metastatic renal cell carcinoma. Poster presented at the

ESMO Congress,

Vienna

, 2012

4. Matsui J, Funahashi Y, Uenaka T et al. Multi-kinase inhibitor E7080 suppresses

lymph node and lung metastases of human mammary breast tumour MDA-MB-

231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and

VEGF-R3 kinase. Clin Cancer Res 2008; 14: 5459-65.

5. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that

targets multiple kinases, has potent anti-tumour activities against stem cell

factor producing human small cell lung cancer H146, based on angiogenesis

inhibition. Int J Cancer 2008; 122: 664-71.

Date of preparation:

September 2012

Job code: Lenvatinib-UK0006